Webinar: Cannabis and dementia: Weeding out the evidence

This integrated KTE webinar event is brought to you by brainXchange in partnership with the Alzheimer Society of Canada and the Canadian Consortium of Neurodegeneration in Aging (CCNA). 

There is increasing interest in the use of cannabinoids as a therapeutic intervention in dementia, particularly for agitation.

By the end of this presentation learners will be aware that: 

• agitation is a common and persistent symptom in those with Alzheimer’s disease
• current pharmacotherapies have modest efficacy and/or poor safety
• there is a pharmacologic rationale for use of cannabinoids
• limited literature has evaluated the efficacy of THC and related compounds for agitation
• a pilot study of a cannabinoid for agitation has recently been completed

Registration is FREE, but space is limited. Click here to Register. If the registration link above does not work, please copy and paste the following into your web browser: https://cannabisanddementianovember6.eventbrite.com

Presenter: Dr. Krista L. Lanctôt has a PhD in Clinical Pharmacology from the University of Toronto, with additional training in pharmacoepidemiology.  She is currently a Senior Neuroscientist in Geriatric Psychiatry and in the Hurvitz Brain Sciences Program at Sunnybrook Research Institute, and the Head of Neuropsychopharmacology Research.  She is a Full Professor of Psychiatry and Pharmacology/Toxicology at the University of Toronto, Toronto, Ontario, Canada.  

Dr. Lanctôt is an active researcher with over 300 publications.  Her group’s research has focused on optimizing the pharmacotherapy of cognition and neuropsychiatric symptoms associated with dementia and in predementia states.  In addition to running randomized controlled trials, her group uses biomarkers, pharmacologic challenge and neuroimaging to further understand these symptoms and target pharmacotherapy. She Co-Chaired the Neuropsychiatric Symptom Professional Interest Area (PIA) within the International Society to Advance Alzheimer's Research and Treatment (ISTAART) and is the co-lead of an international Apathy Workgroup among other international leadership roles.  She currently holds grants as a PI from the National Institutes of Health, Alzheimer’s Drug Discovery Fund, Alzheimer’s Association US, and Canadian Institutes of Health Research.  She is a full member of the School of Graduate Studies in the Faculty of Medicine, University of Toronto, previous winner of the Faculty of Medicine Graduate Education Award, and has successfully supervised 29 graduate students, many of whom have become clinician-scientists.

Connection Details: Technical Requirements

*You will receive an email confirmation shortly after registration, which will include an online link and a teleconference number with an access code.*

Visual Support -- The presentation will be accessible via an Internet connection. This connection can be any web-enabled laptop or desktop computer of your choice.

Audio support -- Audio support for the presentation will be provided through your telephone via a toll-free line.

Please note:

By registering for / participating in this event, you will be added to the brainXchange newsletter list, where you will be emailed bi-monthly newsletters and information on upcoming events. You may unsubscribe at any time 

This event will be recorded.  By choosing to participate in the event, you consent to the recording.  Recordings will be made available on the brainXchange website and on Vimeo. 

If you have further questions, please contact Jillian McConnell at: jillian@brainxchange.ca